dexmedetomidine kabi 100 µg/ml konzentrat zur herstellung einer infusionslösung
fresenius kabi - dexmedetomidin-hydrochlorid - konzentrat zur herstellung einer infusionslösung - 100 µg/ml - dexmedetomidin-hydrochlorid 0.118 mg/ml - dexmedetomidine
levosimendan kabi 2,5 mg/ml konzentrat zur herstellung einer infusionslösung
fresenius kabi austria gmbh - levosimendan -
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
bionolyte + glucose 10 % inf. sol. i.v.
bionolyte + glucose 10 % sol. perf. i.v.
bionolyte + glucose 10 % inf. opl. i.v.
bionolyte + glucose 5 % inf. sol. i.v.
bionolyte + glucose 5 % sol. perf. i.v.
bionolyte + glucose 5 % inf. opl. i.v.
omegaven-fresenius infusionsemulsion
fresenius kabi (schweiz) ag - acidum eicosapentaenoicum, acidum docosahexaenoicum, phospholipida ex ovo purificata, glycerolum, int-rac-alpha-tocopherolum - infusionsemulsion - piscis oleum 10 g corresp. acidum eicosapentaenoicum 1.25-2.82 g et acidum docosahexaenoicum 1.44-3.09 g, phospholipida purificata ex ovo 1.2 g, glycerolum 2.5 g, int-rac-alpha-tocopherolum 15-29.6 mg, natrii oleas, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 100 ml corresp. 470 kj corresp. natrium max. 3.66 mg. - parenterale ernährung - synthetika